MedTrace Logo

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

NCT03372317 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2026-02-11

No results posted yet for this study

Summary

The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.

Conditions

Interventions

DRUG

18F-MK-6240

Results of the 18F-MK-6240 PET scan will be correlated with other observations.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Yaakov Stern

    lead OTHER

Principal Investigators

  • Yaakov Stern, PhD · Columbia University

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2027-01-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03372317 on ClinicalTrials.gov